@FierceMedDev: Masimo hit with subpoena over patient-monitoring tech. More | Follow @FierceMedDev
@VarunSaxena2: House votes to make R&D tax credit permanent. What will Senate do? Seems to prefer 2 year extension. Story via WSJ (sub. req.) | Follow @VarunSaxena2
@MichaelGFierce: Double-locked virus needs two enzyme 'keys' to release drugs. Story via FierceDrugDelivery | Follow @MichaelGFierce
> In data on more than 260,000 defibrillator and pacemaker patients, those who adhered to remote monitoring with St. Jude Medical's ($STJ) Merlin system had more the twice the probability of survival than those without remote monitoring, the company said. More
> Los Angeles' ImaginAb raised $21 million in venture cash to develop modified antibodies for in vivo imaging. Story
> SonaCare Medical has a date with the FDA to discuss its ultrasound-powered prostate cancer treatment, scheduling a hearing and vote with the agency's Gastroenterology and Urology Devices Advisory Committee Panel for Oct. 2. Item
Biotech News
@FierceBiotech: Chutes & Ladders: Bristol-Myers' senior VP of global development retires. Story | Follow @FierceBiotech
@JohnCFierce: Merck KGaA says for the umpteenth time they're going to do some pharma deals. Loaded for bear. More | Follow @JohnCFierce
@DamianFierce: Today in PfAy-Z: Pfizer cozies up to U.K. researchers in 5-year rare disease pact. Article | Follow @DamianFierce
@EmilyMFierce: Antibiotic-resistant genes are almost everywhere. News | Follow @EmilyMFierce
> Biotech's post-boom swoon mars IPO efforts from Radius, Agile. More
> Novartis-backed ImaginAb banks $21M for antibody tech. Article
> Merck wins FDA approval for a once-vaunted cardio drug. Report
Pharma News
@FiercePharma: Pfizer's move on AstraZeneca outrages pols on two continents. More | Follow @FiercePharma
@TracyStaton: Popular at FiercePharmaMarketing: Payers fret about the next drug doomsday: Pricey PCSK9 cholesterol meds. Story | Follow @TracyStaton
@EricPFierce: CEO says Teva will close at least 11 plants, 15% of its network, and 16 more are being evaluated. Article | Follow @EricPFierce
@CarlyHFierce: U.K.'s NICE throws Astellas a bone on Xtandi--or does it? Report | Follow @CarlyHFierce
> Actavis slaps struggling Vivus with generic threat. More
> Merck gets approval for Zontivity for reducing stroke and heart attack risks. Item
> Ranbaxy losses pile up as it awaits the healing powers of Sun. Article